Clinical pharmacology of antifungal compounds.
Prompted by the worldwide surge in fungal infections, the past decade has witnessed a considerable expansion in antifungal drug research. New compounds have entered the clinical arena, and major progress has been made in defining paradigms of antifungal therapies. This article provides an up-to-date review on the clinical pharmacology, indications, and dosage recommendations of approved and currently investigational therapeutics for treatment of invasive fungal infections in adult and pediatric patients.
Groll
Andreas H
AH
Infectious Disease Research Program, Center for Bone Marrow Transplantation, Department of Pediatric Hematology/Oncology, Wilhelms-University Medical Center, Domagkstrasse 9a, 48149 Muenster, Germany. grollan@mednet.uni-muenster.de
Gea-Banacloche
Juan C
JC
Glasmacher
Axel
A
Just-Nuebling
Gudrun
G
Maschmeyer
Georg
G
Walsh
Thomas J
TJ
D000900:Anti-Bacterial Agents / Q000145:classification / Q000378:metabolism / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D015195:Drug Design; D054714:Echinocandins; D005437:Flucytosine / Q000378:metabolism / Q000494:pharmacology; D005656:Fungal Proteins; D006801:Humans; D016867:Immunocompromised Host; D015394:Molecular Structure; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control; D010455:Peptides; D010456:Peptides, Cyclic; D011090:Polyenes / Q000145:classification / Q000493:pharmacokinetics; D014230:Triazoles / Q000145:classification / Q000493:pharmacokinetics
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D005656:Fungal Proteins; D010455:Peptides; D010456:Peptides, Cyclic; D011090:Polyenes; D014230:Triazoles; C007572:echinocandin B; D005437:Flucytosine